menu
    • menu
    [{"orgOrder":0,"company":"Orbital Therapeutics","sponsor":"Beam Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Technology","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"RNA-Based Vaccine","moa":"Undisclosed","graph1":"Technology","graph2":"Discovery","graph3":"Orbital Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Orbital Therapeutics \/ Beam Therapeutics","highestDevelopmentStatusID":"2","companyTruncated":"Orbital Therapeutics \/ Beam Therapeutics"},{"orgOrder":0,"company":"Orbital Therapeutics","sponsor":"Beam Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Immunology","graph2":"Undisclosed","graph3":"Orbital Therapeutics","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Orbital Therapeutics \/ Orbital Therapeutics","highestDevelopmentStatusID":"1","companyTruncated":"Orbital Therapeutics \/ Orbital Therapeutics"},{"orgOrder":0,"company":"Orbital Therapeutics","sponsor":"Arch Ventures","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Series A Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Technology","graph2":"Discovery Platform","graph3":"Orbital Therapeutics","amount2":0.27000000000000002,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Technology","amount2New":0.27000000000000002,"dosageForm":"Undisclosed","sponsorNew":"Orbital Therapeutics \/ Arch Ventures","highestDevelopmentStatusID":"3","companyTruncated":"Orbital Therapeutics \/ Arch Ventures"},{"orgOrder":0,"company":"Orbital Therapeutics","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2025","type":"Acquisition","leadProduct":"OTX-201","moa":"CD19","graph1":"Immunology","graph2":"Preclinical","graph3":"Orbital Therapeutics","amount2":1.5,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":1.5,"dosageForm":"Undisclosed","sponsorNew":"Orbital Therapeutics \/ Bristol Myers Squibb","highestDevelopmentStatusID":"4","companyTruncated":"Orbital Therapeutics \/ Bristol Myers Squibb"}]

    Find Clinical Drug Pipeline Developments & Deals by Orbital Therapeutics

    Menu

    Orbital Therapeutics

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Orbital Therapeutics

                            U.S.A arrow
                            AllPack Indonesia
                            Not Confirmed

                            Orbital Therapeutics

                            U.S.A arrow
                            AllPack Indonesia
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : OTX-201

                            Therapeutic Area : Immunology

                            Study Phase : Preclinical

                            Sponsor : Bristol Myers Squibb

                            Deal Size : $1,500.0 million

                            Deal Type : Acquisition

                            DEALS_DEV arrow-down

                            BMS inks $1.5B deal to pull Orbital into its sphere of influence

                            Details : Acquisition includes OTX-201, an investigational next-generation CAR T-cell therapy designed to reprogram cells in vivo for autoimmune diseases.

                            Product Name : OTX-201

                            Product Type : Cell & Gene Therapy

                            Upfront Cash : $1,500.0 million

                            October 10, 2025

                            Lead Product(s) : OTX-201

                            Therapeutic Area : Immunology

                            Highest Development Status : Preclinical

                            Sponsor : Bristol Myers Squibb

                            Deal Size : $1,500.0 million

                            Deal Type : Acquisition

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Orbital Therapeutics

                            U.S.A arrow
                            AllPack Indonesia
                            Not Confirmed

                            Orbital Therapeutics

                            U.S.A arrow
                            AllPack Indonesia
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Technology

                            Study Phase : Discovery Platform

                            Sponsor : Arch Ventures

                            Deal Size : $270.0 million

                            Deal Type : Series A Financing

                            DEALS_DEV arrow-down

                            Orbital Therapeutics Secures $270 Million in Series A Financing to Unleash Full Potential of RNA Medicines

                            Details : The financing will be used to support the advancement of an Industry-leading, comprehensive platform of RNA technologies and a first-in-class portfolio of programmable RNA-based therapies.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Undisclosed

                            April 26, 2023

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Technology

                            Highest Development Status : Discovery Platform

                            Sponsor : Arch Ventures

                            Deal Size : $270.0 million

                            Deal Type : Series A Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Orbital Therapeutics

                            U.S.A arrow
                            AllPack Indonesia
                            Not Confirmed

                            Orbital Therapeutics

                            U.S.A arrow
                            AllPack Indonesia
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : RNA-Based Vaccine

                            Therapeutic Area : Technology

                            Study Phase : Discovery

                            Sponsor : Beam Therapeutics

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Orbital Therapeutics Launches to Advance New Frontiers of Science with the Next Generation of Innovative RNA M...

                            Details : RNA-based medicines represent fast-growing and disruptive class of therapeutics for a breadth of disease areas. First-generation RNA treatments successfully overcame multiple hurdles, such as the rapid degradation of exogenous RNA, delivery of RNA.

                            Product Name : Undisclosed

                            Product Type : Vaccine

                            Upfront Cash : Inapplicable

                            September 07, 2022

                            Lead Product(s) : RNA-Based Vaccine

                            Therapeutic Area : Technology

                            Highest Development Status : Discovery

                            Sponsor : Beam Therapeutics

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Orbital Therapeutics

                            U.S.A arrow
                            AllPack Indonesia
                            Not Confirmed

                            Orbital Therapeutics

                            U.S.A arrow
                            AllPack Indonesia
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Immunology

                            Study Phase : Undisclosed

                            Recipient : Beam Therapeutics

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Orbital Therapeutics Launches to Advance New Frontiers of Science with the Next Generation of Innovative RNA M...

                            Details : As part of its launch, Orbital and Beam Therapeutics have entered into a license and research collaboration under which Orbital and Beam have each granted the other access to respective RNA technology and non-viral delivery technology.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Undisclosed

                            September 07, 2022

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Immunology

                            Highest Development Status : Undisclosed

                            Recipient : Beam Therapeutics

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth